We are a biotechnology company that develops innovative medicines to improve people's lives.
We discover and develop medicines that offer new and better treatment options for patients in therapeutic areas where there is a high unmet medical need.
With our "Target Discovery Platform", we continue to expand our drug biotechnology pipeline. We are currently working on potential treatments for inflammatory diseases, fibrosis, metabolic diseases and infectious diseases.
Our culture fuels our ambition to bring meaningful medicines to patients, with new modes of action that address the disease and its symptoms, in areas of high unmet need.
In our approach to combatting these diseases, we are committed to listening to patients to understand their daily challenges and unmet needs to inspire our science. We use this insight to inform our medicine development and focus on the health outcomes that truly matter to patients.
We have been active here in Austria as a biopharmaceutical company since 2021 and have set ourselves the goal of providing patients in Austria with new, modern medicines to sustainably improve their quality of life.
Galapagos represents a pioneering spirit, innovation and the creation of new knowledge. We are proud of our research successes and look forward to further expanding our research pipeline together with the clinical experts in our core European markets. Every day, we are committed to the well-being of patients with chronic inflammatory diseases. Our partnerships are our drive, inspiration and the foundation of every innovation.
Mag.pharm. Christine Bellina,
Country Head Alpine
Established over 20 years ago as a target discovery company, we have expanded and diversified and now run three key operational areas – research, development and commercialization.
Across all three areas we employ around 1,300 people, from 50 different nationalities and have operations located in 16 countries across Europe and in the US.
Understanding the true physical and emotional burden of medical conditions fuels our ambition: to bring life-changing treatments to people who need them most. To achieve this we use our three step approach:
Discover: Using human primary cells and patient cells we discover which proteins (targets) play a key role in causing diseases such as rheumatoid arthritis, inflammatory bowel diseases and fibrosis.
Develop: We then develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of a disease.
Deliver: To delivery revolutionary treatments that can save lives.
At Galapagos we believe we can have a meaningful impact on the lives of millions of people who currently live with an inflammatory disease and we are driven by the opportunity to make a difference.
At Galapagos, our mission is to help people live longer, better lives. Our focus is on adding years of life and quality of life.
Paul Stoffels, CEO Galapagos
Our commitment to the treatment of chronic inflammatory diseases is deeply rooted in the history of our company. More than 20 years ago, we set our focus on the discovery of medicines for the therapy of inflammatory diseases, because we believe that there is still a great unmet therapeutic need in this area.
Thanks to our unwavering ambition and desire to improve patients' lives, we have evolved our scope of activities from a pure research company to a commercial-stage European biotech company.
Our ambitious spirit and desire to be the ones to bring our medicines to patients, has seen us evolve from a pure discovery company to a commercial-stage European Biotech.
Chronic inflammatory diseases are currently estimated to affect one in every 20 people in Western society. Rheumatoid Arthritis (RA), Ulcerative Colitis (UC) and Crohn’s Disease (CD) are all examples of inflammatory conditions affecting around 5 million Europeans.
Despite the prevalence of these diseases, current treatment options can still be suboptimal. Many people with ulcerative colitis live in constant dread of experiencing fecal urgency, incontinence, bloody diarrhea, pain and other associated symptoms.
Those with rheumatoid arthritis often continue to live in pain and feel constantly weak and fatigued and there are no identified pathways to finding a cure.
For over 20 years, our pioneering spirit has fuelled our relentless search for innovative medicines with new mechanisms of action.
Most chronic diseases are caused by a malfunction of certain proteins. On our discovery platform, the "Target Discovery Platform", we are focusing on those proteins - which we call "targets" and which play a key role in the development of chronic inflammatory diseases.
We develop molecules that we consider to be potential drugs that can slow down or suppress target proteins, restore the balance and thus positively influence the course of the disease. In doing so, we always pursue the claim of fighting the causes of disease and not just treating the symptoms.
Forschung und Entwicklung ist das Herz von Galapagos und wir freuen uns sehr, jetzt auch hier in Österreich als forschendes europäisches Pharmaunternehmen Präsenz zu zeigen. Unsere Pipeline umfasst Phase-III-Programme bei Entzündungen, Fibrosen und anderen Indikationen. Galapagos verfügt über eine Datenbank mit über 6000 Genen, um potenzielle Targets zu identifizieren, mit denen wir das Fortschreiten der Krankheit beeinflussen können. Auf diese Weise wollen wir die Ursache der Krankheit bekämpfen, anstatt nur die Symptome zu behandeln.
Marcel de Jong,
Galapagos Vice President,
Head of Nordics,
Alpine & Distributor Markets Europe
We are always looking for talented individuals to join us on our journey; who are passionate about life sciences and want to use their knowledge to improve lives.
Make it happen
Act as a pioneer
Raise the bar
Are you ready to join us in the pursue of medical breakthroughs?
Hurry over to our careers page to discover more about opportunities at Galapagos.